Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ODS Evidence-Based Review Program Recruits NCI Official

This article was originally published in The Tan Sheet

Executive Summary

The National Institutes of Health's Office of Dietary Supplements will help stimulate and prioritize supplement research by commissioning several evidence-based reviews from the Agency for Healthcare Research & Quality

You may also be interested in...



SAMe Benefits For Depression, Osteoarthritis, Liver Disease Noted By AHRQ

Dose escalation and risk benefit studies of SAMe for treatment of depression, osteoarthritis and liver disease are among the "promising" areas of future research involving the supplement ingredient identified by the Agency for Healthcare Research & Quality

SAMe Benefits For Depression, Osteoarthritis, Liver Disease Noted By AHRQ

Dose escalation and risk benefit studies of SAMe for treatment of depression, osteoarthritis and liver disease are among the "promising" areas of future research involving the supplement ingredient identified by the Agency for Healthcare Research & Quality

SAMe Benefits For Depression, Osteoarthritis, Liver Disease Noted By AHRQ

Dose escalation and risk benefit studies of SAMe for treatment of depression, osteoarthritis and liver disease are among the "promising" areas of future research involving the supplement ingredient identified by the Agency for Healthcare Research & Quality

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel